Low-Dose Risperidone Treatment for Subjects Suffering From Borderline Personality Disorder

Not Applicable

• Conditions: Borderlone Personality Disorder
• Interventions: Drug: Risperidone

• Registration Number: NCT00633802
• Lead Sponsor: Tel-Aviv Sourasky Medical Center

Brief Summary

Personality disorders are life-long maladaptive behavioral patterns. Borderline personality disorder (BPD) is the leading personality disorder encountered in clinical settings, often associated with tremendous distress. It is characterized by impulsivity, emotional lability, unstable interpersonal relationships, with particular sensitivity to abandonment. BPD patients are prone to self destructive behaviors and all too frequently attempt suicide. When in emotional turmoil, persons with BPD may also develop brief, transient psychotic states.

Psychotherapy for BPD is a common treatment option, but it requires considerable time and specific personnel training, and is therefore not always feasible. Medical treatment is an efficacious alternative, however there is no concensus on drug selection. Some experts have suggested that medical treatment should be selected individually according to the subject's dominant clinical symptom. Several psychopharmacological groups have been proposed: Antidepressants, mood stabilizers, and several novel antipsychotic drugs. The latter are particularly promising since they may produce symptomaic improvement with fewer adverse effects. Risperidone has been shown in a few preliminary studies to be promising in the treatment of various BPD symptoms, but no controlled study has tested it yet. We propose to test the efficacy of risperidone in the treatment of BPD in a double-blind crossover design using both clinical and phsysiological measure.The main hypothesis is that risperidone will be efficient in alleviating BPD core and secondary symptoms.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-04
• Status Verified: 2008-03
• Study First Submitted: 2008-03-04
• Study First Submitted QC: 2008-03-11
• Last Update Submitted: 2008-03-11
• Study First Posted: 2008-03-12
• Last Update Posted: 2008-03-12
• Primary Completion: 2009-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

1. Women with Borderline PD according to DSM-IV
2. Signed informed consent.
3. Age 18-45.

Exclusion Criteria

1. Psychotic disorders (past or present).
2. Substance or alcohol related disorders (past or present).
3. Current major depressive episode.
4. Suicidal risk.
5. History of head trauma, which caused loss of consciousness or peritraumatic amnesia or necessitated hospitalization.
6. Any known psychiatric or general medical condition currently requiring specific medical attention.
7. Current treatment with any antipsychotic, antidepressant drugs or mood stabilizers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Risperidone	-
1	Risperidone	-

Primary Outcome Measures

Name	Time	Method
Clinical Global Improvement Scale	0, 1, 5, 10 week

Trial Locations

Locations (1)

Psychiatric Service, Tel-Aviv Sourasky Medical Center; 🇮🇱 Tel-Aviv, Israel